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Non-communicable diseases (NCDs,
e.g., cardiovascular disease, diabetes, can-
cers, chronic respiratory diseases, neuro-
logical diseases) have been the commonest
cause of death and disability globally for at
least the last three decades [1]. Even in
sub-Saharan Africa, NCDs contribute a
third of the disability-adjusted life year
burden. However, research resources allo-
cated to NCDs in low- and middle-income
countries (LMICs) are trivial [2].
We analyse the interplay between
applied health research in NCDs in high-
income (HICs) and LMICs and demon-
strate that there are opportunities for
mutual advantages. We argue that differ-
ent NCDs are at varying stages in a cycle
of research, policy development, and
action. The research and actions that are
needed depend on the stages of this cycle.
The Interplay between Research
in HICs and LMICs
There is abundant information on the
prevention and control of major NCDs
from HICs, but little attention has been
given to how research in LMICs can
benefit HICs. Box 1 illustrates some of the
forces arising in HICs, which are now
having global impacts on NCDs. Research
methods developed in HICs to study these
forces are equally applicable to LMICs. In
this section we explore this interplay.
There are global benefits from repeat-
ing studies of ‘‘established’’ risk factors in
LMICs. The first indication that there is
no ‘‘safe’’ level of blood cholesterol came
from research in China showing increased
rates of coronary heart disease (CHD)
even at low levels of blood cholesterol [3].
This finding spurred trials of statins among
people with average cholesterol levels,
leading to their widespread use regardless
of blood cholesterol level for high risk
individuals in HICs and LMICs [4].
Replicating health promotion trials for
CHD in LMICs is sensible as rates are
rising, health literacy is low, and there are
strong views about these interventions
[5,6]. A recent large trial of health
promotion in rural India demonstrated
no effects on risk factor profiles or health
knowledge [7]. These findings are disap-
pointing, but may avoid wasteful invest-
ment in this particular approach in both
HICs and LMICs.
The causes of many NCDs are un-
known and therefore ways to prevent them
remain elusive. Combined studies in
LMICs and HICs may be more powerful,
as there is often greater variation in
exposure levels and marked differences in
underlying confounders of risk factor–
NCD associations. For example, breast-
feeding appears to lead to lower blood
pressure and body mass index in children
in HICs, but no associations are found in
LMICs, making it unlikely that the
association in HICs is causal [8].
The upstream determinants of known
causes of NCDs may differ between
LMICs and HICs. High blood pressure,
dyslipidaemia, and smoking are important
proximal causes of cardiovascular disease
globally, but their upstream causes reflect
potentially modifiable social, fiscal, and
legal environments that influence our
behaviours and vary between HICs and
LMICs [9]. Upstream determinants in-
clude economic [10], educational [11],
occupational [12], agricultural [13], and
trade [14] policies, all of which are
adversely affecting risk factors globally.
Some exposures—for example, pesti-
cides—do not occur widely or at high
levels in HICs, making identification of
potential health hazards difficult. Expo-
sures that are orders of magnitudes higher
occur in LMICs and enable harms to be
identified, encouraging control of pesti-
cides globally.
Forces that are near-ubiquitous in HICs
(see Box 1) make it impossible to detect
adverse effects through studies conducted
in HICs [15,16]. For example, asthma
prevalence increases as countries become
more economically productive and clean-
er. The hygiene hypothesis suggests that
lower childhood infection rates may ‘‘pro-
gramme’’ the immune system, leading to
asthma and allergy. The ‘‘hygiene hypoth-
esis’’ cannot be tested only in HICs and
requires global studies [17].
Strong associations have been reported
between HIV/AIDS and cardiometabolic
disorders [18–20], smoking and tubercu-
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losis [21,22], and diabetes and tuberculosis
[23]. Cancers with an infectious aetiology
are more common in LMICs and include
gastric cancer (Helicobacter pylori), hepato-
cellular cancer (hepatatis B and C), and
cervical cancer (human papilloma virus)
[24–26]. Furthermore, the high burden of
infectious diseases and associated chronic
inflammation may exacerbate risks for
some NCDs. The underlying mechanisms
of these associations, new therapeutic
targets, and opportunities to integrate
communicable and NCDs in health sector
reforms may be found by doing studies in
LMICs [27].
Identifying the underlying forces that
influence government and private sector
decision-making on agriculture, trade, and
the built environment requires research.
Understanding how the tobacco industry,
for example, operates in HICs helped
shape the World Health Organization
(WHO) Framework Convention on To-
bacco Control [28], and led to effective
counter-measures that are now being
applied in LMICs. Similar research is
needed in these other areas, particularly
the food sector [29,30]. Reliance on fiscal
and legal interventions based on simple
models examining the direct effects on
consumption and other behaviours are
becoming insufficient as there is growing
understanding of the macroeconomic
‘‘ripple’’ effects of interventions across
economic sectors and between countries
[31].
New approaches to treatment of NCDs
in LMICs are needed. The HIV/AIDS
movement arising in HICs showed the
importance of working with all stakehold-
ers. The largest constituency affected by
NCDs—elderly people—has been ignored
in NCD discourses and alliances [32].
Elderly people constitute a major pressure
group for achieving better, integrated,
holistic services that respond to all their
health needs.
Primary health care, supported by
family and self-care, will form the back-
bone of cost-effective ways of treating and
caring for NCDs and will require research
to develop optimal care models [33].
Research on task shifting to non-medically
qualified practitioners, low-cost near pa-
tient diagnostics, and self and family
management are needed [34], and are
also of relevance to HICs [35]. In
addition, there is a great need to evaluate
prevention interventions in different con-
texts in LMICs, given the current paucity
of evidence. The results should be useful
for informing prevention programmes
with ethnic minorities in HICs.
Summary Points
N Applied health research and development for non-communicable diseases
(NCDs) in low- and middle-income countries (LMICs) is limited, and despite
repeat calls for action, the NCD burden is increasing unchecked.
N NCD research in high-income countries (HICs) and LMICs can result in mutual
advantages in the areas of replication and extending findings; discovering new
causes of NCDs; studying health effects of exposures rare or ubiquitous in HICs;
and exploring links between infectious diseases and NCDs.
N Different NCDs are at varying stages of needing research, policy development,
and action. These stages range from not knowing the population burden of
many NCDs to knowing all we need to take action.
N Changes in the global and national funding agendas will be required to
strengthen the research and health system capacity for NCDs, which should
reduce deaths and disability attributable to NCDs and yield economic
dividends.
Box 1. Globalisation and NCDs
N Tobacco
N Aggressive marketing
N Advertising, product placement
N Political lobbying
N Agricultural production
N Food availability and pricing
N Trade agreements, corporate production, global distribution
N Reduced taxes on unhealthy food imports
N Food preferences and ways of consuming
N Pre-prepared and outside of home
N Multimedia and marketing of western lifestyles and diets
N Carbonated chilled sweetened drinks
N Physical activity
N Promotion of car industry
N Urban design
N Technologies
N Communications (e.g., mHealth; eHealth)
N Pharmaceuticals
N Health care providers
N Social movements
N Knowledge diffusion
N Consumer influence
N Patient interest groups
N Occupational exposures
N Transfer of hazardous industries
N Effects of occupational exposures in vulnerable populations
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The Political Need for Research
The inexorable rise of NCDs in LMICs
has been left unchecked for two decades
with major economic consequences and
avoidable loss of lives. The current situa-
tion is unduly influenced by economic and
commercial interests that negate the
importance of NCDs [36]. Global and
local research, particularly if it can be
conducted in parallel in HICs and LMICs,
can provide powerful arguments for the
need to act globally, as envisaged in the
2011 United Nations high-level meeting
on NCD prevention and control [37].
Situations: Research and Action
Research agendas for LMICs have been
published recently [38–41] proposing
what needs to be done. We are concerned
that ‘‘action’’ only may seem to be pre-
ferable to ‘‘research’’ in LMICs to deal with
the rising NCD burden. Research and
action are not opposite extremes of a con-
tinuum but responses that arise depending
on specific situations, which are summa-
rized in Box 2.
First, the population burden of many
NCDs is not even known. Recent global
burden of disease studies have produced
modeled estimates derived from existing,
but patchy, data of common risk factors
trends to fill the information gap [42–45].
Existing surveillance and monitoring sys-
tems require expanding to include the
major NCDs and risk factors to improve
estimates of burden and monitor trends in
LMICs, as has been done for asthma
[46].
Second, while the population burden of
some diseases is known, the causes aren’t.
Rapid socioeconomic growth in many
LMICs, alongside the severe economic
crisis affecting HICs, and growing mig-
ration and urbanisation are generating
‘‘natural experiments’’ that will allow
investigation of the upstream determi-
nants of common risk factors for NCDs.
For example, a recent study examining
the association of unemployment in an
economic recession and the increasing
number of suicides implicated a lack of
social protection systems in the United
States (compared with other European
countries) as a causal factor [47].
Third, when causes are known there still
needs to be more research into methods of
prevention. Tobacco control topped the
UN high-level meeting’s priority list for
action [37]. The total global population
covered by comprehensive smoke-free
laws increased from 3.1% in 2007 to
5.4% in 2008, providing protection for an
additional 154 million persons [48]. While
this is a big relative improvement in a
short period of time, it is clear that current
strategies are failing the remaining 95% of
the global population, and tobacco use is
still increasing globally.
Fourth, research is needed to improve
patient treatment and care. In parallel
with prevention, improved patient man-
agement is essential [49]. Health services
research, well developed in HICs, is
needed to identify cost-effective treat-
ments, and implementation research is
then required to get research findings into
practice and improve quality of health
care [50]. The potential for improving
NCD health care through health services
research is huge: for example, eHealth;
non-invasive imaging to aid diagnosis; and
integrated patient health records. Many of
these developments, pioneered in LMICs
and evaluated collaboratively using robust
methods, will likely yield global benefits
through reverse innovation [51].
Finally, a situation where what is
needed is known, but not how to imple-
ment it. There are some NCDs for which
it can be argued that sufficient knowledge
is available to act now. For example, five
priority interventions—tobacco control,
salt reduction, improved diets and physical
activity, reduction of hazardous alcohol
intake, and access to essential drugs and
technologies—were recently defined as
requiring ‘‘leadership, prevention, treat-
ment, international cooperation, monitor-
ing and accountability’’ [52]. Experiences
from both HICs and LMICs will be
relevant in finding the best ways forward.
Economics of NCDs and
Funding Research For NCDs
The economic consequences of NCDs
are large and have been well documented.
Estimates of the lost output attributable to
NCDs amount to trillions of dollars a year
[53]; the costs of simple effective interven-
tions are measured in millions of dollars
[54]. Research investments are now re-
quired urgently to fill the implementation
Box 2. Situations: Research and Action Examples
Situation 1: We don’t even know the population burden of many NCDs
We lack data on the burden of disease even for common conditions such as
asthma and epilepsy. Adding NCD modules to existing health and demographic
surveillance systems that provide burden of disease estimates for maternal and
child health is underway and will provide additional sources of robust data [60].
Situation 2: We know the population burden but we don’t know the causes
Understanding the ‘‘upstream’’ causes of NCDs can make use of natural
experiments such as the introduction of urban mass transport systems on
physical activity [61]; social and economic change on risk factors [62]; and rural
development strategies (e.g., new roads, employment schemes) on obesity and
diabetes. The Prospective Urban Rural Epidemiology [63] study runs in 600
communities in 17 countries to examine the impact of urbanisation on health.
Situation 3: We know the causes but we need more research into methods of
prevention
Occupational exposures make a substantial contribution to NCD in industrialised
countries, but their relevance in LMICs has not been assessed [64]. This is of
particular concern given that many hazardous industries are situated in LMICs [65].
For example, in India’s asbestos industry, health risks are discounted: ‘‘That lung
cancer deaths have been caused by asbestos fibre has not been proved in India,’’
argues John Nicodemus, executive director of the Asbestos Cement Products
Manufacturers’ Association, a New Delhi–based industry organization [66].
Situation 4: We need research to improve patient treatment and care
Management of NCDs through mHealth technology, task shifting from doctors to
other health workers, and self-management all require robust evaluation. They
may also be highly relevant to cost-constrained health services in HICs.
Situation 5: ‘‘We know what is needed—but not how to implement it’’
Salt restriction lowers blood pressure but is difficult for individuals to do as much
dietary salt is hidden in processed foods. In the UK, bread manufacturers have
voluntarily reduced the salt content of bread slowly, which should result in
reductions in population levels of blood pressure [67].
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gap between what works and achieving
health gain in practice. The UN high-level
meeting on NCDs formally acknowledged
that resources devoted to combating
NCDs are not commensurate with the
magnitude of the problem [37]; the
meeting noted that domestic, bilateral,
regional, and multilateral channels of
funding will be required.
Most health research funding is spent in
HICs, but the greatest need, both in
scientific and public health terms, is in
the rest of the world [55]. Previous calls to
action on NCDs over the last decade have
had some impact on funding [54], which
may generate further enthusiasm for
funding research in LMICs.
While most LMICs do have a budget
for NCD-related work [56], there is no
room to innovate and evaluate strategies
for NCDs. Much of the research and
development relevant to implementation is
country-specific and requires national
funding. The WHO has recommended
that the extra resources needed could
come from increasing efficiency of revenue
collection; improving access to social
health insurance; increased tobacco and
alcohol taxes; and including NCDs as a
priority for official development assistance
[57]. A further need is to develop capacity
to conduct applied NCD health research.
This is limited in most LMICs. Training
and partnerships with experienced NCD
researchers and institutions should be a
high priority for development pro-
grammes.
The time has now come for all health-
related research and development fun-
ders—global, regional, and national— to
acknowledge the existence of NCDs and
rise to the challenges they present. For
example, the United Kingdom’s Depart-
ment for International Development has
identified the importance of NCDs in
contributing to poverty and has initiated
a mental health programme in several
LMICs. Hopefully other programmes will
follow [58]. A first step would be for global
and bilateral agencies, major national
health research councils, and charities to
publish their spending by disease catego-
ries to track their contribution in meeting
the World Health Assembly’s recent NCD
targets of a 25% reduction in NCD
mortality by 2025 [59].
Conclusions
There are unique opportunities for
answering critical research questions about
NCDs in LMICs (see Box 3). The list
reflects our experiences and disciplinary
perspectives from public health, epidemi-
ology, primary care, and health policy.
Where to begin will depend on the
scientific capacity to deliver, national
priorities, and the funds available. The
important point is to make a start
somewhere. The 2011 UN high-level
meeting provided a strong context for
research and action. A major shift in
attitudes from knowing what needs to be
done towards using research to prioritise,
evaluate, monitor and, incrementally,
improve health outcomes is urgently
needed. Action and research are required:
they are intimately entwined and the
balance between them will depend on
the situation and the health problem.
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Box 3. A Proposed Research Agenda for NCDs in Low- and
Middle-Income Countries
N Measuring the burden of NCDs, mental health, and injuries
N Improving synthetic methods
N Integrating and improving quality of health information systems
N Causal inference:
N ‘‘Upstream’’ causes of common NCD risk factor distributions
N Occupational exposures and NCDs
N Genetic variation
N Mendelian randomisation approaches to identifying environmental determi-
nants of NCDs
N Pharmacogenetics for stratified medicine to minimise risks and maximise
benefits of treatments
N Urbanisation/migration
N Influence of urbanisation on lifestyles
N Health impacts of urban and rural development programmes
N Prevention and control of NCDs
N Cost-effectiveness studies of preventive interventions targeted at individuals
N Cost-effectiveness studies of fiscal and legal means of health protection
N Developing and promoting healthier models of food production, marketing,
and consumption
N Health systems research
N Strengthening of primary care services
N Health care financing for universal primary care coverage
N Task-shifting, family and self-care, and eHealth for NCD prevention and care
N Policy research
N Evaluation of health impacts of public policies on food security, trade,
agriculture, and rural/urban development
N Implementation research
N Use of health technology assessment and audit to improve quality of health
care
N Examination of facilitators and barriers to establishing cross-sectoral working
for health
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